Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.44 |
| ▸ | HTR3B | O95264 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 3/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 5/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398431 | 1.00 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1743759 | 1.00 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5551527 | 0.80 | PLAU (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5551530 | 0.80 | PLAU (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1227408 | 0.80 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5551549 | 0.80 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1227404 | 0.80 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL7456811 | 0.79 | HTR3E (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5546939 | 0.78 | SLC22A2 (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5546942 | 0.78 | SLC22A2 (0.48) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-22 | — | — | US | claimed |
| WO-2024168123-A1 | SYNTHESIS OF CORE 2 O-SIALYL LEWIS-X POLYSACCHARIDES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-08-15 | — | — | WO | claimed |
| EP-4306546-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | Daiichi Sankyo Company, Limited (JP) | 2024-01-17 | — | — | EP | claimed |
| WO-2022191313-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | 第一三共株式会社 | 2022-09-15 | — | — | WO | claimed |
| CN-108299523-B | Disaccharide and preparation method thereof, and preparation method of polysaccharide | 上海医药工业研究院 | 2021-05-14 | — | — | CN | claimed |
| CN-109627270-B | Chemical synthesis method of Pseudomonas aeruginosa O11 serotype O antigen oligosaccharide | 江南大学 | 2020-12-29 | — | — | CN | claimed |
| US-10870710-B2 | Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof | MEDIMMUNE LIMITED (GB) | 2020-12-22 | — | — | US | claimed |
| CN-107226830-B | Chemical synthesis method of spinetoram | BEIJING UNIVERSITY OF TECHNOLOGY (CN) | 2019-12-10 | — | — | CN | claimed |
| US-20260144856-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-05-28 | — | — | US | disclosed |
| EP-4486753-B1 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | REVAGENIX INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12606587-B2 | Protected tetrasaccharides, their process of preparation and their use as transglucosylase acceptor substrates in the chemo-enzymatic synthesis of Shigella flexneri specific oligosaccharides | INSTITUT PASTEUR (FR) | 2026-04-21 | — | — | US | disclosed |
| US-20260008803-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | ACADEMIA SINICA (TW) | 2026-01-08 | — | — | US | disclosed |
| US-20260007733-A1 | Specific Saccharide Fragment for Development of Vibrio Cholerae Vaccines | UNIV JIANGNAN (CN) | 2026-01-08 | — | — | US | disclosed |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-13 | — | — | US | disclosed |
| EP-1191931-A4 | 1-(4-SULFAMYLARYL)-3-SUBSTITUTED-5-ARYL-2-PYRAZOLINES AS INHIBITORS OF CYCLOOXYGENASE-2 | UNIV TEMPLE (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376519-B1 | ANTIINFLAMMATORY AGENTS, ANTICANCER AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION | 2002-04-23 | — | — | US | disclosed |
| EP-1191931-A1 | 1-(4-SULFAMYLARYL)-3-SUBSTITUTED-5-ARYL-2-PYRAZOLINES AS INHIBITORS OF CYCLOOXYGENASE-2 | Temple University of the Commonwealth System of Higher Education (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076503-A1 | 1-(4-SULFAMYLARYL)-3-SUBSTITUTED-5-ARYL-2-PYRAZOLINES AS INHIBITORS OF CYCLOOXYGENASE-2 | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076983-A1 | 1-(4-ARYLSULFONYL)-3-SUBSTITUTED-5-ARYL-2-PYRAZOLINES AS INHIBITORS OF CYCLOOXYGENASE-2 | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-12-21 | — | — | WO | disclosed |
| US-4299831-A | 2-Trifluoromethyl-3-quinoline carboxamides, analgesic and anti-inflammatory compositions and methods employing them | ROUSSEL UCLAF (FR) | 1981-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007733-A1 | Specific Saccharide Fragment for Development of Vibrio Cholerae Vaccines | STT3B, ST3GAL3, HACD3 | HTR3E 1037/4885HTR3B 1372/4885HTR3A 1878/4885 |
| US-12606587-B2 | Protected tetrasaccharides, their process of preparation and their use as transglucosylase acceptor substrates in the chemo-enzymatic synthesis of Shigella flexneri specific oligosaccharides | GALE, SI, GBA3 | HTR3E 1958/4885HTR3B 2518/4885HTR3A 2215/4885 |
| US-20240279364-A1 | GLYCAN, AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN | FUT6, ST6GAL1, NEU2 | HTR3E 3267/4885HTR3B 2163/4885HTR3A 2778/4885 |
| US-20260144856-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | PKLR, RPS17, OSTC | HTR3E 4555/4885HTR3B 4606/4885HTR3A 4816/4885 |
| US-20260008803-A1 | SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME | NEU2, ST6GAL1, NEU3 | HTR3E 1496/4885HTR3B 3284/4885HTR3A 2107/4885 |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | FUT6, FUT5, ST3GAL3 | HTR3E 4034/4885HTR3B 3636/4885HTR3A 3134/4885 |
| US-10870710-B2 | Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof | PSPH, STT3B, DDOST | HTR3E 4804/4885HTR3B 4762/4885HTR3A 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.